Welcome, Guest. Please login or register.
June 22, 2024, 04:24:47 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55129
  • Total Topics: 4851
  • Online Today: 117
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 74
Total: 74


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Shortened Epclusa Regimen Not as Effective for Recent Hep C Infection  (Read 6928 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Shortening the standard 12-week regimen of Epclusa (sofosbuvir/velpatasvir) to just six weeks for those recently infected with hepatitis C virus (HCV) is associated with an unacceptably high rate of viral relapse after the end of therapy.

That’s according to a recent study presented by Gail Matthews, PhD, of the Kirby Institute at the University of New South Wales in Australia, at the 2020 Conference on Retroviruses and Opportunistic Infections in Boston last week.

The REACT study was a randomized controlled trial comparing a six-week (short) Epclusa regimen with a 12-week (standard) regimen among people who contracted HCV within the past 12 months, including people who inject drugs and people with HIV coinfection. The participants were randomized evenly into the two treatment arms.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.